Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745900 | 1.00 | HDAC6 (0.37) | HDAC6TBXAS1CYP1A2CYP2D6USP2 | |
| SCHEMBL7149141 | 0.87 | HDAC6 (0.37) | HDAC6TBXAS1DYRK1ACLK1ICAM1 | |
| SCHEMBL6749766 | 0.84 | HDAC6 (0.40) | HDAC6LMNAMEN1CYP3A4KMT2A | |
| SCHEMBL6749761 | 0.84 | HDAC6 (0.40) | HDAC6LMNAMEN1CYP3A4KMT2A | |
| SCHEMBL6747667 | 0.82 | KDM4E (0.40) | HDAC6LMNAKMT2A | |
| SCHEMBL6747666 | 0.82 | KDM4E (0.40) | HDAC6LMNAKMT2A | |
| SCHEMBL6750296 | 0.79 | HDAC6 (0.42) | HDAC6LMNAMEN1KMT2A | |
| SCHEMBL6745730 | 0.78 | HDAC6 (0.43) | HDAC6MEN1KMT2AICAM1 | |
| SCHEMBL6747454 | 0.77 | HDAC6 (0.43) | HDAC6LMNAMEN1CYP3A4KMT2A | |
| SCHEMBL6747321 | 0.77 | CYP11B1 (0.34) | HDAC6CYP2D6LMNACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | HDAC6 1953/4885TBXAS1 80/4885CYP1A2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.